
    
      This is a randomized, paralleled study. Patients will be divided into two groups of treatment
      and control. all of them will receive conventional treatment based on specific condition,
      including digitalis, milrinone, furosemide, beta-blocker blues, Angiotensin-Converting Enzyme
      Inhibitors (ACEI), angiotension receptor blocker (ARB), and antiplatelet aggregation etc.
      Treatment group patients will receive hUC-MSC. Follow-up visit will occur on 3 months, 6
      months, and 12 months after the cell transfusion. Vital signs, blood routine test, urine
      routine test, liver function examination, etc, will be placed to evaluate the safety of
      hUC-MSC treatment. And the change of symptoms to evaluate the efficacy.
    
  